All patients were stabilized in the hospital first with a continuous IV infusion of low-dose milrinone 0. This is problematic for NYHA class IV patients who are refractory to oral medical management, since their therapeutic options are few and their risk of death may increase without intermittent outpatient inotropic therapy.
Oral medical therapy was maximized when possible. The mean duration of milrinone treatment in this combination-treatment group was days range, 14—1, days. If the patient did not remain clinically stable, weaning was implemented more slowly or for fewer hours per day. Meanwhile, the total number of hospital days decreased from to a The mean duration of IV milrinone therapy and follow-up was days range, 14—1, days.
All patients were followed up in a specialized heart failure clinic. The duration of hospital stay for this group decreased from days during the 6 months before treatment to days during the first 6 months of treatment a The demographics and characteristics of this patient population are shown in Table I.
Abstract Phosphodiesterase inhibitors such as milrinone can relieve symptoms and improve hemodynamics in patients with advanced congestive heart failure.
All patients had been unresponsive to the maximum oral dosages of digitalis, diuretics, and ACE inhibitors and could not be weaned from milrinone while in the hospital. If the patient remained clinically stable, milrinone was discontinued after the 2-week period.
Hospital admissions during the previous 6 months and admissions within 6 months after milrinone initiation stayed the same. Results According to data from invasive hemodynamic studies in the patient records, all patients treated with IV milrinone showed substantially increased cardiac output.
A peripherally inserted central catheter was used to administer the milrinone, except in 1 patient who required a subclavian catheter.
Nonetheless, long-term milrinone administration is controversial. Adrenergic beta-antagonists, heart failure, congestive, milrinone Advanced heart failure is an increasingly prevalent problem in cardiology. As the population ages and therapy for coronary artery disease improves, more people are developing advanced congestive heart failure CHF.
Tex Heart Inst J ; Statistical methods are as follows: Weaning consisted of discontinuing milrinone for 12 hours every other day for 1 week and then for 12 hours every day for 1 week.
However, hypotension and weakness may occur during the usual 6-week period of up-titration.Cardiac output and pulmonary capillary wedge pressure improved at least 20% with IV milrinone. The mean duration of IV milrinone therapy and follow-up was days (range, 14–1, days).
In 51 of the 65 patients, β-blocker therapy was successfully initiated during IV milrinone therapy. Cardiovascular Drugs Throughout the Continuum of Care Carol Jacobson RN, MN killarney10mile.com Determinants of Cardiac Output Venous tone Body Position Intrathoracic Intrapericardial BP value does not tell you WHY the BP is low – must evaluate determinants of BP and treat the cause Low BP could be due to.
Feneck [14 x 14 Feneck, R.O. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group. European Multicenter Trial Group. Am Heart J. Background— Low cardiac output syndrome (LCOS), affecting up to 25% of neonates and young children after cardiac surgery, contributes to postoperative morbidity and mortality.
This study evaluated the efficacy and safety of prophylactic milrinone in pediatric patients at high risk for developing LCOS. Methods and Results— The study was a double. Abstract.
We assessed the effect of milrinone on myocardial function in pediatric patients with postoperative low cardiac output syndrome by index of myocardial performance in a prospective, open-label, nonrandomized, consecutive study.
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Retrieved 25 August, Torres, M., Pharm, D., & Nieves, J. A. ().Download